Survivin, a member of the inhibitors of apoptosis family, is down-regulated in breast carcinoma effusions

American Journal of Clinical Pathology

Volumn 128, Issue 3, 2007, Pages 389-397

  Kleinberg, Lilach ^a   Flørenes, Vivi Ann ^a   Nesland, Jahn M ^a,b   Davidson, Ben ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Breast carcinoma; Chemotherapy; IAP; Inhibitors of apoptosis; Serous effusions; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; HORMONE RECEPTOR; KI 67 ANTIGEN; METHOTREXATE; PROTEIN LIVIN; SURVIVIN; TUMOR PROTEIN; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ADULT; ADVANCED CANCER; AGED; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARCINOMA CELL; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; DOWN REGULATION; EFFUSION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; LYMPH NODE METASTASIS; PARAMETER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID TUMOR; TUMOR LOCALIZATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA; DISEASE-FREE SURVIVAL; DOWN-REGULATION; FEMALE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; KI-67 ANTIGEN; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM PROTEINS; PLEURAL EFFUSION, MALIGNANT; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 34748881394     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/E899BG1282M5D505     Document Type: Article

References (29)

1. Cancer Registry of Norway. Cancer in Norway, 2004. Oslo, Norway: Cancer Registry of Norway; 2006.
2. Hausheer FH, Yarbro JW. Diagnosis and treatment of malignant pleural effusion. Semin Oncol. 1985;12:54-75.
3. Martinez-Moragon E, Aparicio J, Sanchis J, et al. Malignant pleural effusion: prognostic factors for survival and response to chemical pleurodesis in a series of 120 cases. Respiration. 1998;65:108-113.
4. Wilkes JD, Fidias P, Vaickus L, et al. Malignancy-related pericardial effusion: 127 cases from the Roswell Park Cancer Institute. Cancer. 1995;76:1377-1387.
5. Dieterich M, Goodman SN, Rojas-Corona RR, et al. Multivariate analysis of prognostic features in malignant pleural effusions from breast cancer patients. Acta Cytol. 1994;38:945-952.
6. Banerjee AK, Willetts I, Robertson JF, et al. Pleural effusion in breast cancer: a review of the Nottingham experience. Eur J Surg Oncol. 1994;20:33-36.
7. Reed JC. Dysregulation of apoptosis in cancer. J Clin Oncol. 1999;17:2941-2953.
8. Nachmias B, Ashhab Y, Ben-Yehuda D. The inhibitor of apoptosis protein family (IAPs): an emerging therapeutic target in cancer. Semin Cancer Biol. 2004;14:231-243.
9. Schimmer AD. Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res. 2004;64:7183-7190.
10. Liston P, Fong WG, Korneluk RG. The inhibitors of apoptosis: there is more to life than bcl2. Oncogene. 2003;22:8568-8580.
11. Yang L, Cao Z, Yan H, et al. Coexistence of high levels of apoptotic signaling and inhibitor of apoptosis proteins in human tumor cells: implication for cancer specific therapy. Cancer Res. 2003;63:6815-6824.
12. Zhang Y, Wang Y, Gao W, et al. Transfer of siRNA against XIAP induces apoptosis and reduces tumor cells growth potential in human breast cancer in vitro and in vivo. Breast Cancer Res Treat. 2006;96:267-277.
13. Wu M, Yuan S, Szporn AH, et al. Immunocytochemical detection of XIAP in body cavity effusions and washes. Mod Pathol. 2005;18:1618-1622.
14. O'Driscoll L, Linehan R, Kennedy SM, et al. Lack of prognostic significance of survivin, survivin-ΔEx3, survivin-2B, galectin-3, bag-1, bax-α and MRP-1 mRNAs in breast cancer. Cancer Lett. 2003;201:225-236.
15. Ryan B, O'Donovan N, Browne B, et al. Expression of survivin and its splice variants survivin-2B and survivin-ΔEx3 in breast cancer. Br J Cancer. 2005;92:120-124.
16. Span PN, Sweep FC, Wiegerinck ET, et al. Survivin is an independent prognostic marker for risk stratification of breast cancer patients. Clin Chem. 2004;50:1986-1993.
17. Kennedy SM, O'Driscoll L, Purcell R, et al. Prognostic importance of survivin in breast cancer. Br J Cancer. 2003;88:1077-1083.
18. Sohn DM, Kim SY, Baek MJ, et al. Expression of survivin and clinical correlation in patients with breast cancer. Biomed Pharmacother. 2006;60:289-292.
19. Tanaka K, Iwamoto S, Gon G, et al. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res. 2000;6:127-134.
20. Ryan BM, Konecny GE, Kahlert S, et al. Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. Ann Oncol. 2006;17:594-604.
21. Davidson B, Reich R, Lazarovici P, et al. Altered expression and activation of the nerve growth factor receptors TrkA and p75 provide the first evidence of tumor progression to effusion in breast carcinoma. Breast Cancer Res Treat. 2004;83:119-128.
22. Davidson B, Konstantinovsky S, Nielsen S, et al. Altered expression of metastasis-associated and regulatory molecules in effusions from breast cancer patients: a novel model for tumor progression. Clin Cancer Res. 2004;10:7335-7346.
23. Davidson B, Konstantinovsky S, Kleinberg L, et al. The mitogen-activated protein kinases (MAPK) p38 and JNK are markers of tumor progression in breast carcinoma. Gynecol Oncol. 2006;102:453-461.
24. Davidson B, Nielsen S, Christensen J, et al. The role of desmin and N-cadherin in effusion cytology: a comparative study using established markers of mesothelial and epithelial cells. Am J Surg Pathol. 2001;25:1405-1412.
25. Kleinberg L, Flørenes VA, Silins I, et al. Nuclear expression of survivin is associated with improved survival in metastatic ovarian carcinoma. Cancer. 2007;109:228-238.
26. Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene. 2003;22:8581-8589.
27. Davidson B, Espina V Flørenes VA, et al. Proteomic profiling of malignant ovarian cancer effusions: survival and injury pathways discriminate clinical outcome. Clin Cancer Res. 2006;12:791-799.
28. Kleinberg L, Lie AK, Flørenes VA, et al. Expression of inhibitors of apoptosis (IAP) family members in malignant mesothelioma. Hum Pathol. 2007;38:986-994.
29. Rodriguez JA, Span SW, Ferreira CG, et al. CRM1-mediated nuclear export determines the cytoplasmic localization of the antiapoptotic protein survivin. Exp Cell Res. 2002;275:44-53.